← Retour au Screener

Sector: Santé
Open in Terminal → CLDXLive chart · Key metrics · News · Smart money

Celldex Therapeutics

CLDX Mid Cap

Healthcare · Biotechnology

Mis à jour: Aug 2, 2026, 22:14 UTC

33,08 €
-1.1% aujourd'hui
52W: 17,14 € – 35,02 €
52W Low: 17,14 € Position: 89.1% 52W High: 35,02 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
3453.65x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
2,6 Md €
Capitalisation boursière
Croissance du CA
-97.8%
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-48.94%
Rentabilité des capitaux propres
Beta
0.9
Sensibilité au marché
Positions vendeuses
11.59%
% du flottant vendu à découvert
Volume moyen
994,362
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
15 analysts
Avg. Price Target
49,60 €
+49.94% upside
Target Range
29,55 € – 86,90 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 198 Exchange: NCM

Celldex Therapeutics en bref

Celldex Therapeutics (CLDX) is currently trading at 33,08 € with a market capitalization of 2,6 Md €. The 52-week range spans from 17,14 € to 35,02 €; the current price is 5.6% below the yearly high. Year-over-year revenue growth stands at -97.8%.

💰 Dividende

Celldex Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

15 analystes évaluent Celldex Therapeutics (CLDX) au consensus : Achat Fort. L'objectif de cours moyen est de 49,60 €, soit un potentiel de +49.94% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 29,55 € à 86,90 €.

Celldex Therapeutics : la thèse d'investissement en détail

Celldex Therapeutics (CLDX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 49.94% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -97.8% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Short interest sits at 11.59% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

  • The analyst consensus price target implies 49.94% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Strong Buy
  • Bilan solide avec faible endettement (D/E 0.42)
Points faibles
  • CA en contraction (-97.8% sur un an)
  • Positions vendeuses élevées (11.59%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
29,64 €
+11.58% vs. cours
MM 200 jours
25,77 €
+28.36% vs. cours
Sous le plus haut 52s
−5.6%
35,02 €
Au-dessus du plus bas 52s
+93%
17,14 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Risque de marché (Bêta)
0.9 · Proche du marché
Évolue moins que le marché global
Positions vendeuses
11.59% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
0.42 · Faible
Dette totale / capitaux propres

The data points to relatively defensive market behavior, elevated short interest (11.59%).

Trading Data

50-Day MA: 29,64 €
200-Day MA: 25,77 €
Volume: 875,735
Avg. Volume: 994,362
Short Ratio: 5.8
P/B Ratio: 5.55x
Debt/Equity: 0.42x
Free Cash Flow: -109 734 372 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Celldex Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut